Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Fast release of data leads to rapid changes in clinical practice for drug-eluting stents

Fast release of data leads to rapid changes in clinical practice for drug-eluting stents

July 29, 2009

E-mail, search engines, smart phones and other new technologies that can disseminate new medical information quickly led to an almost immediate change in clinical practice for drug-eluting stents, according to a study reported in Circulation: Cardiovascular Quality and Outcomes.

With the rapid-fire release of data, studies presented at medical conferences in the age of instant information can have an almost immediate impact on patient treatment, said Matthew T. Roe, M.D., M.H.S., lead author of the study and associate professor of medicine at Duke University Medical Center and at the Duke Clinical Research Institute in Durham N.C.




"We were interested in whether practice patterns changed after the presentation of these studies," he said. "That's indeed what we showed."

Researchers examined data from two large patient registries that showed from January - September 2006 (before the data were released) about 90 percent of patients with a type of heart attack known as a non-ST-elevation myocardial infarction (NSTEMI) who underwent coronary stent implantation received drug-eluting stents, which are coated with anti-proliferative drugs to prevent narrowings from recurring within the coronary arteries.

In September 2006, a number of studies were presented at the European Society of Cardiology Scientific Sessions that found drug-coated stents were associated with a higher risk of late stent thrombosis, or blood clots in the artery treated with the stent, compared with bare metal stents which were not coated with anti-proliferative drugs. By the end of March 2007, the use of drug-eluting stents fell to 67 percent and usage continued to drop to 58 percent by the beginning of 2008, Roe said.

"There was a rapid change of practice patterns after these presentations in September 2006," he said.

"To our knowledge, this was the most rapid change in practice patterns in cardiology. We presume it was because of a rapid uptake of information."

The swiftness in which practice patterns changed signaled that speedy distribution of information through media and scientific outlets may become the "predominant stimulus for changes in practice in the future," researchers said.

Researchers examined records of 54,662 patients with NSTEMI, which included 27,329 patients who had stents implanted. The information was gathered from two large registries: CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) during 2006, which transitioned into ACTION Registry-GWTG (Get With the Guidelines) beginning in January, 2007. Hospital or patient characteristics didn't change during the study, researchers said.

The study's results show the need for experts to put results in context, Roe said.

"This study demonstrates the dynamic shifts that are occurring in the distribution of medical information," said Clyde W. Yancy, M.D. president of the American Heart Association and medical director at Baylor Heart and Vascular Institute in Dallas, Texas. "The opportunity to widely share important findings that promptly impact practice is becoming a powerful tool to drive change. The requirements for prompt but thorough peer review and nimble responsiveness to new data are evident. Managing this new health IT space will require focus, assessment and realignment."

Co-authors are: Anita Y. Chen, M.S.; Christopher P. Cannon, M.D.; Sunil Rao, M.D.;
John Rumsfeld, M.D., Ph.D.; David J. Magid, M.D., M.P.H.; Ralph Brindis, M.D., M.P.H.; Lloyd W. Klein, M.D.; W. Brian Gibler, M.D.; E. Magnus Ohman, M.D.; and Eric D. Peterson, M.D., M.P.H.

Individual author disclosures can be found on the manuscript.

CRUSADE was funded by Schering-Plough Corporation and the Bristol-Myers Squibb/Sanofi Aventis Pharmaceuticals Partnership. These organizations also contribute funding to ACTION Registry-GWTG.

American Heart Association, Inc.



Related Drug-eluting Stents Current Events and Drug-eluting Stents News Articles Drug-eluting Stents Current Events and Drug-eluting Stents News RSS Drug-eluting Stents Current Events and Drug-eluting Stents News RSS
Higher carotid arterial stenting rates associated with poorer clinical outcomes
Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine.

Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

SPIRIT IV trial shows everolimus stent sets new standard for event-free survival
Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

Drug-eluting stents safe, effective for treatment of chronic total occlusions
A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
The Cardiovascular Research Foundation (CRF) announced that results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) were published online June 15 in the journal Circulation.

NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patients
NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine.

Drug-eluting stents prove more effective, equally as safe as bare-metal stents
The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published today in The New England Journal of Medicine.

Drug-eluting stents found safe, superior to bare metal stents
Drug-eluting stents were safe and superior to bare metal stents in preventing death and heart attacks among 262,700 "real-world" patients enrolled in a nationwide registry of cardiovascular disease, according to researchers from Duke University Medical Center.

Promising 3-year data: Saving limbs with drug-eluting stents
Attempts to treat critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death (gangrene) and amputation.
More Drug-eluting Stents Current Events and Drug-eluting Stents News Articles
Handbook of Drug-Eluting Stents

Handbook of Drug-Eluting Stents
by Patrick W. Serruys (Author), Anthony H. Gershlick (Author)

Over the past few years, the focus in interventional cardiology research has centered on reducing restenosis with the use of antiproliferative pharmacological agents. The use of these drugs, hitherto, has failed, most probably because of low active drug levels at the target site. This problem led to the development of local drug delivery using stents, since they can serve as a reservoir for local drug administration and are in immediate contract with the coronary artery wall, thus ensuring maximum delivery of the pharmacological agent. Drug-eluting stents provide an entirely new spectrum of potential therapies for restenosis. Handbook of Drug-Eluting Stents, under the editorial direction of Patrick Serruys, one of the world's leading interventional cardiologists, and Tony Gershlick, a...

Drug-eluting Stents: Are they Safe?

Drug-eluting Stents: Are they Safe?

Drug-eluting stents are metal mesh tubes coated with medication that keep arteries from re-blocking after angioplasty. These devices have been the solution for millions of people around the world. However, recent studies have raised concerns about associated risks. Join Dr. Yeung and colleagues as they discuss the safety of these popular devices

This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply.

  The 2009-2014 Outlook for Drug-Eluting Stents in Europe
by Icon Group International (Author)

This econometric study covers the outlook for drug-eluting stents in Europe. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-a-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is...

Colombo's Tips & Tricks for Drug Eluting Stents

Colombo's Tips & Tricks for Drug Eluting Stents
by Antonio Colombo (Author), Goran Stankovic (Author)

A trailblazer in interventional cardiology, Dr. Antonio Colombo combines his vast experience with that of Goran Stankovic and distinguished colleagues to share tips and tricks for dealing with diseased coronary arteries. Whether discussing his 'crushing and kissing' techniques or the stenting of tortuous vessels in the elderly, Dr. Colombo and his colleagues' texts and case commentaries provide the reader with succinct and simple advice based on personal experience. They provide the most comprehensive and practical guide available for those involved in coronary artery stenting. The images are all down-loadable in Powerpoint and will be of tremendous use to instructors and students alike.

  IMPROVED JANUS FLEX DRUG ELUTING STENT LAUNCHED IN EUROPE.: An article from: Biotech Equipment Update
by Thomson Gale (Publisher)

This digital document is an article from Biotech Equipment Update, published by Thomson Gale on April 1, 2006. The length of the article is 498 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: IMPROVED JANUS FLEX DRUG ELUTING STENT LAUNCHED IN EUROPE.
Publication: Biotech Equipment Update (Newsletter)
Date: April 1, 2006
Publisher: Thomson Gale
Volume: 14 Issue: 4 Page: NA

Distributed by Thomson Gale

  MEDIVAS/ESTRACURE SIGN PACT FOR DRUG ELUTING STENT.: An article from: Biotech Equipment Update
by Worldwide Videotex (Publisher)

This digital document is an article from Biotech Equipment Update, published by Worldwide Videotex on September 1, 2005. The length of the article is 488 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: MEDIVAS/ESTRACURE SIGN PACT FOR DRUG ELUTING STENT.
Publication: Biotech Equipment Update (Newsletter)
Date: September 1, 2005
Publisher: Worldwide Videotex
Volume: 13 Issue: 9 Page: NA

Distributed by Thomson Gale

  Up to six drug-eluting stents to hit U.S. market: the new models are expected to improve deliverability and increase competition, which might reduce costs.: An article from: Internal Medicine News
by Mitchel L. Zoler (Author)

This digital document is an article from Internal Medicine News, published by Thomson Gale on March 15, 2006. The length of the article is 1035 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Up to six drug-eluting stents to hit U.S. market: the new models are expected to improve deliverability and increase competition, which might reduce costs.
Author: Mitchel L. Zoler
Publication: Internal Medicine News (Magazine/Journal)
Date: March 15, 2006
Publisher: Thomson Gale
Volume: 39 Issue: 6 Page: 57(1)

Distributed by Thomson...

  Pro & Con: is it too early to jump on the bandwagon for drug-eluting stents?: An article from: Family Practice News
by International Medical News Group (Publisher)

This digital document is an article from Family Practice News, published by International Medical News Group on December 1, 2002. The length of the article is 885 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Pro & Con: is it too early to jump on the bandwagon for drug-eluting stents?
Publication: Family Practice News (Magazine/Journal)
Date: December 1, 2002
Publisher: International Medical News Group
Volume: 32 Issue: 23 Page: 10(1)

Distributed by Thomson...

Drug Eluting Stents: Anti-Inflammatory Approach To Prevent Restenosis After Stent Implantation (Acta Biomedica Lovaniensia)

Drug Eluting Stents: Anti-Inflammatory Approach To Prevent Restenosis After Stent Implantation (Acta Biomedica Lovaniensia)
by Yanming Huang (Author)



  Is it too early to jump on the bandwagon for drug-eluting stents? (Pro & Con).: An article from: Internal Medicine News
by International Medical News Group (Publisher)

This digital document is an article from Internal Medicine News, published by International Medical News Group on December 1, 2002. The length of the article is 856 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Is it too early to jump on the bandwagon for drug-eluting stents? (Pro & Con).
Publication: Internal Medicine News (Magazine/Journal)
Date: December 1, 2002
Publisher: International Medical News Group
Volume: 35 Issue: 23 Page: 10(1)

Distributed by Thomson...

© 2009 BrightSurf.com